Reduced CD20 expression yields inferior survival in patients with B-cell lymphoma treated with CD20×CD3 antibodies
Emil Ramsø Kyvsgaard(University of Copenhagen), Simon Husby(Copenhagen University Hospital), Michael Møller(Hospital South West Jutland), Trine Grantzau(Rigshospitalet), Trine Trab(University of Copenhagen), Thomas Stauffer Larsen(Odense University Hospital), Jacob Haaber(Odense University Hospital), Linea Cecilie Melchior(Rigshospitalet), Michael Roost Clausen(Vejle Sygehus), Carsten Utoft Niemann(Copenhagen University Hospital), Morten Grauslund(Rigshospitalet), Martin Hutchings(University of Copenhagen), Lene Dissing Sjø(Rigshospitalet), Mia Dahl Sørensen(University of Southern Denmark), Caroline Hasselbalch Riley(Rigshospitalet), Kirsten Grønbæk(University of Copenhagen)
Cited by 2
Related Papers
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568